ProQR Therapeutics
PRQR
64 hedge funds and large institutions have $80M invested in ProQR Therapeutics in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
3% more funds holding
Funds holding: 62 → 64 (+2)
3% less capital invested
Capital invested by funds: $82.4M → $80M (-$2.41M)
2.77% less ownership
Funds ownership: 38.45% → 35.68% (-2.8%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$980K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$607K |
| 3 |
Two Sigma Investments
New York
|
+$422K |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$413K |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$3.08M |
| 2 |
Millennium Management
New York
|
-$2.33M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.29M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$761K |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$471K |
PRQR Hedge Fund Activity: Q3 2025 in Review
64 of the 7,626 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2025, worth a combined $80M — down 2.9% from $82.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PRQR positions and 6 closed out — a net gain of 2 holders — while 14 added to existing stakes and 12 trimmed.
The largest buyer was Aberdeen Group, adding an estimated $980K. The largest seller was Woodline Partners, cutting an estimated $3.08M.
- 64 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2025, up from 62 in Q2 2025.
- Funds reported $80M of ProQR Therapeutics stock for Q3 2025, down 2.9% quarter-over-quarter.
- 8 funds opened new ProQR Therapeutics positions in Q3 2025 and 6 closed out, a net change of +2 holders.
- The largest ProQR Therapeutics buyer in Q3 2025 was Aberdeen Group, an estimated $980K added.
- The largest ProQR Therapeutics seller in Q3 2025 was Woodline Partners, an estimated $3.08M sold.
Based on aggregated 13F filings for Q3 2025.